Autologous hematopoietic stem cell transplantation in multiple sclerosis
A meta-analysis
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received October 6, 2016
- Accepted in final form February 6, 2017
- First Published April 28, 2017.
Article Versions
- Previous version (April 28, 2017 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Maria Pia Sormani, PhD,
- Paolo A. Muraro, MD,
- Irene Schiavetti, PhD,
- Alessio Signori, PhD,
- Alice Laroni, MD,
- Riccardo Saccardi, MD and
- Gian Luigi Mancardi, MD
- Maria Pia Sormani, PhD,
NONE
NONE
Merck Serono, TEVA, Genzyme, Novartis, Biogen, Roche
NONE
NONE
NONE
NONE
Merck Serono, Biogen, TEVA, Genzyme, Roche, Novartis, GeNeuro
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paolo A. Muraro, MD,
NONE
NONE
Dr. Muraro has received travel support and speaker honoraria from Novartis, Bayer HealthCare, Bayer Pharma, Biogen Idec, Merck-Serono and Sanofi Aventis.
Guest Editor, PLOS Medicine
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Funder: Medical Research Council Type of grant: Project Grant Title: Pathfinder: An experimental medicine study of the 18 kD translocator protein as a novel neuroimmunodulatory target for multiple sclerosis Duration: 3 years 2016-19
NONE
Funder: UK Multiple Sclerosis Society / UK Stem Cell Foundation Type of grant: Collaborative Project Grant Title: A phase II trial of autologous mesenchymal stem cell transplantation in highly active multiple sclerosis ? Duration:2012-17 PI: Muraro Co-applicants: Chandran, Dazzi, Miller, Nicholas
NONE
NONE
NONE
NONE
NONE
NONE
- Irene Schiavetti, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alessio Signori, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Alice Laroni, MD,
(1) Sanofi (2) Merck
NONE
(1) travel, Teva (2) speaker honoraria, Biogen (3)speaker honoraria, Teva (4) speaker honoraria, Novartis
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, funding to a workshop organized by me
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Riccardo Saccardi, MD and
NONE
NONE
honoraria for lecturing from Sanofi
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gian Luigi Mancardi, MD
NONE
NONE
Honoraria for lecturing , travel expenses for attending meetings and finacial support for research from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva Pharmaceuticals
Associate Editor of Neurological Sciences
NONE
NONE
Honoraria for speaking activities from Companies (Biogen Dompe', Bayer Schering)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Italian Multiple Sclerosis Society (AISM) Grants 2001-R-38 and 2002-R-36
NONE
NONE
NONE
NONE
NONE
NONE
- From the Departments of Health Sciences (M.P.S., I.S., A.S.) and Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health (A.L., G.L.M.), University of Genoa, Italy; Division of Brain Sciences (P.A.M.), Imperial College, London, UK; IRCCS Azienda Ospedaliera Universitaria San Martino-IST (A.L., G.L.M.), Genoa; and Cell Therapy and Transfusion Medicine Unit (R.S.), Careggi University Hospital, Firenze, Italy.
- Correspondence to Dr. Sormani: mariapia.sormani{at}unige.it
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. David E. Vaillancourt and Dr. Shannon Y. Chiu
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Research Article
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple SclerosisA Real-world Case SeriesRichard S. Nicholas, Elijah E. Rhone, Alice Mariottini et al.Neurology, July 12, 2021 -
Article
Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple SclerosisGiacomo Boffa, Luca Massacesi, Matilde Inglese et al.Neurology, January 20, 2021 -
Editorial
Autologous hematopoietic stem cell transplantation for MSSafer than previously thoughtJoachim Burman, Robert J. Fox et al.Neurology, April 28, 2017 -
Views & Reviews
Unraveling treatment response in multiple sclerosisA clinical and MRI challengeClaudio Gasperini, Luca Prosperini, Mar Tintoré et al.Neurology, December 26, 2018